Copenhagen, 2014-05-01 16:00 CEST (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) will host an R&D and business briefing for the investment community on Wednesday, 21 May in New York City. The meeting offers an opportunity to learn more about allergy immunotherapy and will highlight the recent advances and future potential for ALK’s allergy immunotherapy business.
Help employers find you! Check out all the jobs and post your resume.
